Invention Grant
- Patent Title: Method for treating pulmonary hypertension
- Patent Title (中): 治疗肺动脉高压的方法
-
Application No.: US13211923Application Date: 2011-08-17
-
Publication No.: US08414891B2Publication Date: 2013-04-09
- Inventor: Roger Johns , Xingwu Teng , Dechun Li
- Applicant: Roger Johns , Xingwu Teng , Dechun Li
- Applicant Address: US MD Baltimore
- Assignee: The Johns Hopkins University
- Current Assignee: The Johns Hopkins University
- Current Assignee Address: US MD Baltimore
- Agency: Johns Hopkins Technology Transfer
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61P9/12 ; C07K16/24

Abstract:
We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
Public/Granted literature
- US20120039839A1 Hypoxia Induced Mitogenic Factor Public/Granted day:2012-02-16
Information query